Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

DNA methylation inhibitor

DRUG CLASS:

DNA methylation inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

DNA methyltransferase inhibitor (0)

recombinant methionine α, γ-lyase (0)

DNA methyltransferase inhibitor (0)

recombinant methionine α, γ-lyase (0)

›

TET2 deletion + DNMT3A mutation	Melanoma	TET2 deletion + DNMT3A mutation	Melanoma	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D
TET2 deletion + DNMT3A mutation	Kidney Cancer	TET2 deletion + DNMT3A mutation	Kidney Cancer	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D
TET2 deletion + DNMT3A mutation	Lung Cancer	TET2 deletion + DNMT3A mutation	Lung Cancer	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D
TET2 deletion + DNMT3A mutation	Breast Cancer	TET2 deletion + DNMT3A mutation	Breast Cancer	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D	TdCyd Sensitive: D – Preclinical TdCyd Sensitive : D
HYAL4 V1	Bladder Cancer	HYAL4 V1	Bladder Cancer	gemcitabine + EPI01 Sensitive: D – Preclinical gemcitabine + EPI01 Sensitive : D	gemcitabine + EPI01 Sensitive: D – Preclinical gemcitabine + EPI01 Sensitive : D